Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 3
2003 4
2004 5
2005 8
2006 8
2007 6
2008 7
2009 10
2010 17
2011 16
2012 14
2013 17
2014 16
2015 33
2016 21
2017 27
2018 50
2019 39
2020 40
2021 53
2022 50
2023 50
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

450 results

Results by year

Filters applied: . Clear all
Page 1
Exosomes secreted from cardiomyocytes suppress the sensitivity of tumor ferroptosis in ischemic heart failure.
Yuan Y, Mei Z, Qu Z, Li G, Yu S, Liu Y, Liu K, Shen Z, Pu J, Wang Y, Wang C, Sun Z, Liu Q, Pang X, Wang A, Ren Z, Wang T, Liu Y, Hong J, Xie J, Li X, Wang Z, Du W, Yang B. Yuan Y, et al. Among authors: wang z. Signal Transduct Target Ther. 2023 Mar 27;8(1):121. doi: 10.1038/s41392-023-01336-4. Signal Transduct Target Ther. 2023. PMID: 36967385 Free PMC article.
Spatially resolved metabolomics to discover tumor-associated metabolic alterations.
Sun C, Li T, Song X, Huang L, Zang Q, Xu J, Bi N, Jiao G, Hao Y, Chen Y, Zhang R, Luo Z, Li X, Wang L, Wang Z, Song Y, He J, Abliz Z. Sun C, et al. Among authors: wang z. Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):52-57. doi: 10.1073/pnas.1808950116. Epub 2018 Dec 17. Proc Natl Acad Sci U S A. 2019. PMID: 30559182 Free PMC article.
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Liu Y, Zhu XZ, Xiao Y, Wu SY, Zuo WJ, Yu Q, Cao AY, Li JJ, Yu KD, Liu GY, Wu J, Sun T, Cui JW, Lv Z, Li HP, Zhu XY, Jiang YZ, Wang ZH, Shao ZM. Liu Y, et al. Cell Res. 2023 May;33(5):389-402. doi: 10.1038/s41422-023-00795-2. Epub 2023 Mar 27. Cell Res. 2023. PMID: 36973538 Free PMC article. Clinical Trial.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Chen L, et al. Clin Cancer Res. 2022 Jul 1;28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313. Clin Cancer Res. 2022. PMID: 35247906 Free PMC article.
450 results